If a patient wishes to become pregnant, how should lithium therapy be managed?

Management of Lithium in Women Planning Pregnancy

If a patient on lithium wishes to become pregnant, you should conduct thorough preconception counseling about risks and benefits, consider continuing lithium if she is stable (as discontinuation carries high relapse risk), but if stopping is chosen, taper gradually at least 2 months before conception—then restart immediately postpartum given the extremely high risk of postpartum relapse. 1, 2

Preconception Counseling and Risk Assessment

The FDA classifies lithium as Pregnancy Category D, indicating evidence of fetal risk 1. Recent large studies confirm an association between first-trimester lithium exposure and increased risk of congenital malformations, particularly cardiac anomalies including Ebstein's anomaly, though the absolute risk is lower than historically reported 2. One study documented a major cardiac malformation (hypoplastic left heart syndrome) in 34 followed pregnancies 3.

Critical counseling points:

• Discuss the teratogenic risk versus the substantial risk of bipolar relapse if lithium is discontinued
• Explain that 60% of patients who discontinue medication relapse postpartum, compared to 27% who continue treatment 4
• Review genetic counseling for bipolar disorder inheritance 4

Three Management Pathways

Option 1: Continue Lithium Throughout Pregnancy (Preferred for Severe/Unstable Disease)

This is reasonable when:

• Patient has severe bipolar disorder with history of multiple relapses
• Previous medication trials failed
• Patient achieved stability only on lithium 5, 2

Management protocol:

• Maintain lowest effective therapeutic level (individualized dosing) 5
• Increase monitoring frequency: weekly lithium levels in third trimester 2
• Arrange high-resolution ultrasound with fetal anomaly scanning at 20 weeks 2
• Plan delivery at specialized hospital with psychiatric, obstetric, and neonatal monitoring capabilities 2
• Discontinue lithium 24-48 hours before delivery or reduce dose to prevent neonatal toxicity 2
• Restart immediately after delivery at pre-pregnancy dose to prevent postpartum relapse 2

Option 2: Discontinue for First Trimester, Restart After

Consider when:

• Patient has milder disease course
• Good response to alternative medications exists
• Patient strongly prefers minimizing fetal exposure 2

Specific steps:

• Taper gradually over 2-4 weeks (abrupt discontinuation increases relapse risk)
• Stop at least 2 months before attempting conception 4
• Consider alternative mood stabilizers during first trimester (though note: valproate has higher teratogenic risk than lithium; carbamazepine is an alternative) 6, 4
• Restart lithium after first trimester if needed for disease control 2
• Mandatory restart immediately postpartum given 60% relapse risk without medication 4

Option 3: Switch to Alternative Before Conception

Only if:

• Patient has not yet achieved optimal stability on lithium
• Time permits trial of alternative medication before conception
• Alternative agents (carbamazepine, certain antipsychotics) may be considered, though each has its own risk profile 4

Critical Monitoring During Pregnancy

Lithium pharmacokinetics change significantly:

• Renal clearance increases during pregnancy, requiring dose adjustments
• Volume of distribution increases
• Monitor levels more frequently than standard (weekly in third trimester) 2
• Watch for signs of toxicity: diarrhea, vomiting, tremor, ataxia, drowsiness, muscular weakness 1

Drug interactions requiring vigilance:

• NSAIDs (increase lithium levels significantly) 1
• Diuretics and ACE inhibitors (reduce renal clearance, increase toxicity risk) 1
• Avoid these medications during pregnancy if possible

Postpartum Management

Immediate postpartum period is highest risk:

• Restart lithium immediately after delivery if discontinued 2
• Target high therapeutic lithium level for relapse prevention 2
• Monitor for 72 hours minimum in hospital setting
• Breastfeeding is generally discouraged as lithium is excreted in breast milk 1, though some recent evidence suggests individualized approaches may be considered with close infant monitoring 5

Common Pitfalls to Avoid

• Do not abruptly discontinue lithium—this dramatically increases relapse risk
• Do not use standard therapeutic ranges—pregnancy requires individualized dosing with more frequent monitoring
• Do not delay postpartum restart—the postpartum period carries the highest relapse risk
• Do not forget to coordinate care—delivery must occur at facility with psychiatric, obstetric, and neonatal expertise 2
• Do not prescribe NSAIDs during pregnancy—they significantly increase lithium toxicity risk 1

The decision ultimately depends on disease severity, prior treatment response, and patient preference after thorough informed consent, but maintaining lithium with enhanced monitoring is increasingly recognized as a viable option for many patients 5, 2.